華策影視(300133.SZ):影業上海擬進行增資並引入員工持股平台
格隆匯12月17日丨華策影視(300133.SZ)公佈,公司為增強全資子公司華策影業(上海)有限公司(“影業上海”或“標的公司”)運營能力,激發內生動力與活力,同意影業上海進行增資並引入員工持股平台。
員工持股平台擬以總額10207.68萬元人民幣對標的公司增資並取得其合計40.50%的股權(即標的公司10207.68萬元註冊資本)。此次增資完成後,影業上海註冊資本由15000萬元增加至25207.68萬元。
員工持股平台內的有限合夥人涉及公司部分董事、監事和高級管理人員,根據《深圳證券交易所創業板股票上市規則》的有關規定,認定員工持股平台為公司的關聯方,此次增資構成關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.